Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
| Total | Transactions | Amount |
| Buys | 21 | $18,097,110 |
| Sells | 54 | $14,064,385 |
| Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
| 07 Jan 2025 20:02 | ANTX | AN2 Therapeutics Inc | DAY LUCY | Chief Financial Officer | 03 Jan 2025 | Sale | 2,957 | 1.341 | 3,965 | D |
| 07 Jan 2025 20:00 | ANTX | AN2 Therapeutics Inc | CHANDA SANJAY | Chief Development Officer | 03 Jan 2025 | Sale | 2,957 | 1.341 | 3,965 | D |
| 07 Jan 2025 19:57 | ANTX | AN2 Therapeutics Inc | PRIOR STEPHEN DAVID | Chief Strategy Officer | 03 Jan 2025 | Sale | 2,029 | 1.341 | 2,721 | D |
| 07 Jan 2025 19:57 | ANTX | AN2 Therapeutics Inc | EIZEN JOSHUA M | See Remarks | 03 Jan 2025 | Sale | 9,663 | 1.341 | 12,958 | D |
| 10 Dec 2024 20:46 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 06 Dec 2024 | Purchase | 12,711 | 1.445 | 18,367 | I |
| 10 Dec 2024 20:46 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 06 Dec 2024 | Purchase | 6,517 | 1.4466 | 9,427 | I |
| 10 Dec 2024 20:46 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 09 Dec 2024 | Purchase | 12,289 | 1.4303 | 17,577 | I |
| 10 Dec 2024 20:46 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 09 Dec 2024 | Purchase | 18,483 | 1.4287 | 26,407 | I |
| 10 Dec 2024 20:46 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 10 Dec 2024 | Purchase | 5,000 | 1.4924 | 7,462 | I |
| 10 Dec 2024 20:46 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 10 Dec 2024 | Purchase | 5,000 | 1.4935 | 7,468 | I |
| 27 Nov 2024 19:07 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 26 Nov 2024 | Purchase | 12,500 | 1.3934 | 17,418 | I |
| 27 Nov 2024 19:07 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 26 Nov 2024 | Purchase | 12,500 | 1.3942 | 17,428 | I |
| 27 Nov 2024 19:07 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 27 Nov 2024 | Purchase | 25,000 | 1.4169 | 35,422 | I |
| 27 Nov 2024 19:07 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 27 Nov 2024 | Purchase | 25,000 | 1.4167 | 35,418 | I |
| 27 Nov 2024 16:16 | ANTX | AN2 Therapeutics Inc | ZAKRZEWSKI JOSEPH S | Director | 27 Nov 2024 | Purchase | 2,000 | 1.4 | 2,800 | D |
| 21 Nov 2024 18:00 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 19 Nov 2024 | Purchase | 75,000 | 1.0337 | 77,528 | I |
| 21 Nov 2024 18:00 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 19 Nov 2024 | Purchase | 75,000 | 1.0364 | 77,730 | I |
| 21 Nov 2024 18:00 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 20 Nov 2024 | Purchase | 25,000 | 1.16 | 29,000 | I |
| 21 Nov 2024 18:00 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 20 Nov 2024 | Purchase | 25,000 | 1.1548 | 28,870 | I |
| 20 Nov 2024 16:11 | ANTX | AN2 Therapeutics Inc | ZAKRZEWSKI JOSEPH S | Director | 18 Nov 2024 | Purchase | 20,000 | 0.9998 | 19,996 | D |
| 20 Nov 2024 16:11 | ANTX | AN2 Therapeutics Inc | ZAKRZEWSKI JOSEPH S | Director | 19 Nov 2024 | Purchase | 5,000 | 1.01 | 5,050 | D |
| 18 Nov 2024 20:51 | ANTX | AN2 Therapeutics Inc | EASOM ERIC | Chief Executive Officer | 18 Nov 2024 | Purchase | 50,000 | 0.9994 | 49,970 | I |
| 14 Aug 2024 20:24 | ANTX | AN2 Therapeutics Inc | LEONARD BRADEN MICHAEL | 10% | 14 Aug 2024 | Purchase | 1,500,000 | 1.04 | 1,560,000 | I |
| 13 Aug 2024 17:03 | ANTX | AN2 Therapeutics Inc | RA CAPITAL MANAGEMENT, L.P. | 10% | 09 Aug 2024 | Sale | 114,759 | 1.08 | 123,940 | I |
| 13 Aug 2024 17:03 | ANTX | AN2 Therapeutics Inc | RA CAPITAL MANAGEMENT, L.P. | 10% | 09 Aug 2024 | Sale | 3,410,335 | 1.08 | 3,683,162 | I |
| 19 Jan 2024 19:32 | ANTX | AN2 Therapeutics Inc | ZAKRZEWSKI JOSEPH S | Director | 18 Jan 2024 | Sale | 100,000 | 19.1141 | 1,911,410 | I |
| 18 Jan 2024 18:19 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director | 16 Jan 2024 | Sale | 15,907 | 19.65 | 312,573 | I |
| 18 Jan 2024 18:19 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director | 16 Jan 2024 | Sale | 84,093 | 19.65 | 1,652,427 | I |
| 18 Jan 2024 18:18 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 16 Jan 2024 | Sale | 15,907 | 19.65 | 312,573 | I |
| 18 Jan 2024 18:18 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 16 Jan 2024 | Sale | 84,093 | 19.65 | 1,652,427 | D |
| 17 Jan 2024 17:03 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 12 Jan 2024 | Sale | 719 | 21.91 | 15,753 | I |
| 17 Jan 2024 17:03 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 12 Jan 2024 | Sale | 706 | 21.92 | 15,476 | I |
| 12 Jan 2024 17:08 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 10 Jan 2024 | Sale | 1,800 | 21.92 | 39,456 | I |
| 12 Jan 2024 17:08 | ANTX | AN2 Therapeutics Inc | READNOUR ROBIN SHANE | Director | 10 Jan 2024 | Sale | 1,869 | 21.93 | 40,987 | I |
| 11 Jan 2024 19:59 | ANTX | AN2 Therapeutics Inc | KRAUSE KEVIN MICHAEL | Chief Strategy Officer | 09 Jan 2024 | Sale | 7,417 | 20.1385 | 149,367 | D |
| 04 Jan 2024 18:06 | ANTX | AN2 Therapeutics Inc | KRAUSE KEVIN MICHAEL | Chief Strategy Officer | 02 Jan 2024 | Sale | 2,583 | 20.1189 | 51,967 | D |
| 04 Jan 2024 18:05 | ANTX | AN2 Therapeutics Inc | EASOM ERIC | Chief Executive Officer | 02 Jan 2024 | Sale | 2,777 | 20.0945 | 55,802 | D |
| 16 Nov 2023 18:59 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 14 Nov 2023 | Sale | 288 | 16.146 | 4,650 | I |
| 16 Nov 2023 18:59 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 14 Nov 2023 | Sale | 1,522 | 16.146 | 24,574 | D |
| 16 Nov 2023 18:57 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 14 Nov 2023 | Sale | 288 | 16.146 | 4,650 | I |
| 16 Nov 2023 18:57 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 14 Nov 2023 | Sale | 1,522 | 16.146 | 24,574 | I |
| 03 Oct 2023 19:21 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 02 Oct 2023 | Sale | 902 | 16.07 | 14,495 | I |
| 03 Oct 2023 19:21 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 02 Oct 2023 | Sale | 4,770 | 16.07 | 76,654 | I |
| 03 Oct 2023 19:21 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 29 Sep 2023 | Sale | 15,764 | 16.28 | 256,638 | I |
| 03 Oct 2023 19:21 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 29 Sep 2023 | Sale | 83,337 | 16.28 | 1,356,726 | I |
| 03 Oct 2023 19:13 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 02 Oct 2023 | Sale | 4,770 | 16.07 | 76,654 | D |
| 03 Oct 2023 19:13 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 02 Oct 2023 | Sale | 902 | 16.07 | 14,495 | I |
| 03 Oct 2023 19:13 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 29 Sep 2023 | Sale | 15,764 | 16.28 | 256,638 | I |
| 03 Oct 2023 19:13 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 29 Sep 2023 | Sale | 83,337 | 16.28 | 1,356,726 | D |
| 29 Sep 2023 17:41 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 28 Sep 2023 | Sale | 1,356 | 16.11 | 21,845 | I |
| 29 Sep 2023 17:41 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 28 Sep 2023 | Sale | 7,160 | 16.11 | 115,348 | D |
| 29 Sep 2023 17:41 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 27 Sep 2023 | Sale | 134 | 16.07 | 2,153 | I |
| 29 Sep 2023 17:41 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 27 Sep 2023 | Sale | 707 | 16.07 | 11,361 | D |
| 29 Sep 2023 17:40 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 28 Sep 2023 | Sale | 7,160 | 16.11 | 115,348 | I |
| 29 Sep 2023 17:40 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 28 Sep 2023 | Sale | 1,356 | 16.11 | 21,845 | I |
| 29 Sep 2023 17:40 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 27 Sep 2023 | Sale | 134 | 16.07 | 2,153 | I |
| 29 Sep 2023 17:40 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 27 Sep 2023 | Sale | 707 | 16.07 | 11,361 | I |
| 15 Sep 2023 17:40 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 13 Sep 2023 | Sale | 64 | 16 | 1,024 | I |
| 15 Sep 2023 17:40 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 13 Sep 2023 | Sale | 336 | 16 | 5,376 | I |
| 15 Sep 2023 17:17 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 13 Sep 2023 | Sale | 64 | 16 | 1,024 | I |
| 15 Sep 2023 17:17 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 13 Sep 2023 | Sale | 336 | 16 | 5,376 | D |
| 08 Sep 2023 16:59 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 07 Sep 2023 | Sale | 2,841 | 16.05 | 45,598 | D |
| 08 Sep 2023 16:59 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 07 Sep 2023 | Sale | 537 | 16.05 | 8,619 | I |
| 08 Sep 2023 16:59 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 06 Sep 2023 | Sale | 598 | 16.02 | 9,580 | I |
| 08 Sep 2023 16:59 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 06 Sep 2023 | Sale | 3,164 | 16.02 | 50,687 | D |
| 08 Sep 2023 16:57 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 07 Sep 2023 | Sale | 537 | 16.05 | 8,619 | I |
| 08 Sep 2023 16:57 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 07 Sep 2023 | Sale | 2,841 | 16.05 | 45,598 | I |
| 08 Sep 2023 16:57 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 06 Sep 2023 | Sale | 598 | 16.02 | 9,580 | I |
| 08 Sep 2023 16:57 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 06 Sep 2023 | Sale | 3,164 | 16.02 | 50,687 | I |
| 25 Aug 2023 16:31 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 23 Aug 2023 | Sale | 64 | 16 | 1,024 | I |
| 25 Aug 2023 16:31 | ANTX | AN2 Therapeutics Inc | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | 10% | 23 Aug 2023 | Sale | 336 | 16 | 5,376 | D |
| 25 Aug 2023 16:30 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 23 Aug 2023 | Sale | 64 | 16 | 1,024 | I |
| 25 Aug 2023 16:30 | ANTX | AN2 Therapeutics Inc | AZIZ KABEER | Director , 10% | 23 Aug 2023 | Sale | 336 | 16 | 5,376 | I |
| 22 Aug 2023 17:01 | ANTX | AN2 Therapeutics Inc | RA CAPITAL MANAGEMENT, L.P. | 10% | 18 Aug 2023 | Purchase | 1,777,778 | 9 | 16,000,002 | I |
| 15 May 2023 20:01 | ANTX | AN2 Therapeutics Inc | EASOM ERIC | Chief Executive Officer | 15 May 2023 | Purchase | 10,000 | 5.377 | 53,770 | I |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)